Image-guided radiation therapy vendor ViewRay reported preliminary revenue increases for its fourth quarter and fiscal year 2021.
For the quarter (end-December 31), ViewRay's revenue was approximately $20 million, up 11% from $18 million in the same period in 2020. For the full year, the company posted revenues of approximately $70 million, up 23% from last year's $57 million.
The company said it also received seven new orders for its MRIdian MRI-guided radiation therapy system in 2021, compared with five new orders in the same period in 2020. For the year, it received 28 new orders for systems -- an increase of 65% compared with 17 new orders in 2020.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
